Form 8-K TG THERAPEUTICS, INC. For: May 27

false 0001001316 0001001316 2026-05-27 2026-05-27

 ​​

 

 

 

 

 

 

Date of report (Date of earliest event reported): May 27, 2026

 

(Exact Name of Registrant as Specified in Charter)

 

 ​

Morrisville, North Carolina 27560

(Address of Principal Executive Offices)

 

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

 

Securities filed pursuant to Section 12(b) of the Act:

 

 ​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

On May 27, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS). A copy of the press release is being filed herewith as Exhibit 99.1 and incorporated into this Item by reference.

 

 

 

 ​

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.